Healthcare -
Biotechnology - NASDAQ - US
$ 2.005
-5.42 %
$ 75.3 M
Market Cap
-0.52
P/E
1. INTRINSIC VALUE
Balance Sheet
Biomea Fusion, Inc.
| Current Assets | 68.3 M |
| Cash & Short-Term Investments | 58.3 M |
| Receivables | 0 |
| Other Current Assets | 10.1 M |
| Non-Current Assets | 11.6 M |
| Long-Term Investments | 0 |
| PP&E | 10.6 M |
| Other Non-Current Assets | 988 K |
| Current Liabilities | 21.7 M |
| Accounts Payable | 12.9 M |
| Short-Term Debt | 2.08 M |
| Other Current Liabilities | 6.66 M |
| Non-Current Liabilities | 6.69 M |
| Long-Term Debt | 6.69 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Biomea Fusion, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 144 M |
| Operating Income | -144 M |
| Other Expenses | -5.64 M |
| Net Income | -138 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Biomea Fusion, Inc.
| Net Income | -138 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | -362 K |
| Stock-Based Compensation | 19.1 M |
| Change in Working Capital | -5.15 M |
| Others | -562 K |
| Free Cash Flow | -120 M |
Wall Street Analysts Price Targets
Biomea Fusion, Inc.
Wall Street analysts predict an average 1-year price target for BMEA of $16.4 , with forecasts ranging from
a
low of
$5 to a high of $40 .
BMEA Lowest Price Target
Wall Street Target
5 USD
149.38%
BMEA Average Price Target
Wall Street Target
16.4 USD
716.71%
BMEA Highest Price Target
Wall Street Target
40 USD
1895.01%
4. DIVIDEND
ANALYSIS
BMEA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Biomea Fusion, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
101 K USD 1
6-9 MONTHS
55.4 K USD 1
9-12 MONTHS
7. News
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 2 weeks ago
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company's common stock. The shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Plan (the “Plan”).
globenewswire.com
- 2 weeks ago
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 2 weeks ago
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, reported fourth quarter and full year 2024 financial results and corporate highlights.
globenewswire.com
- 2 weeks ago
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
The heavy selling pressure might have exhausted for Biomea Fusion (BMEA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
- 2 weeks ago
Biomea Fusion Announces Leadership Transition
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role.
globenewswire.com
- 3 weeks ago
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025 Conference in Amsterdam, The Netherlands. The new findings support icovamenib's potential as a first-in-class, disease-modifying therapy by targeting beta-cell restoration, enhancing insulin secretion, and sustaining glycemic improvements beyond icovamenib's treatment period.
globenewswire.com
- 3 weeks ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 3, 2025, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company's common stock. The shares underlying the employee's stock options will vest 1/16 on a quarterly basis over four years, subject to the employee's continued employment with the Company on such vesting dates. The above-described award was made under Biomea's 2023 Inducement Equity Plan (the “Plan”).
globenewswire.com
- 1 month ago
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025).
globenewswire.com
- 1 month ago
Biomea's icovamenib meets HbA1c standards in T2D, says H.C. Wainwright
Biomea on Tuesday announced positive topline results from its Phase 2 COVALENT-111 trial evaluating icovamenib in patients with type 2 diabetes, with key takeaways including icovamenib displaying a statistically significant placebo-adjusted mean HbA1c reduction of 0.36% in the pre-specified per-protocol patient population and reduction of 0.42% after 12 weeks of treatments, H.C. Wainwright tells investors. Topline COVALENT-111 results validate the potential of icovamenib for long-term glycemic control with short-term treatment duration, the firm says. H.C. Wainwright made no change to its Buy rating or $40 price target.
https://thefly.com
- 4 months ago
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
On Tuesday, Biomea Fusion Inc. BMEA revealed topline results from the ongoing COVALENT-111 study of icovamenib in patients with type 2 diabetes (T2D).
benzinga.com
- 4 months ago
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced positive topline results from the ongoing COVALENT-111 study, evaluating the efficacy, safety and tolerability of icovamenib in patients with type 2 diabetes (T2D).
globenewswire.com
- 4 months ago
8. Profile
Summary
Biomea Fusion, Inc. BMEA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 75.3 M
Dividend Yield
0.00%
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Contact
900 Middlefield Road, Redwood City, CA, 94063
https://biomeafusion.com
IPO
Date
April 16, 2021
Employees
106
Officers
Dr. Thorsten Kirschberg Ph.D.
Executive Vice President of Chemistry
Ms. Naomi Cretcher
Chief People Officer
Dr. Michael J. M. Hitchcock Ph.D.
Interim Chief Executive Officer & Director
Dr. Stephan Morris M.D.
Chief Development Officer
Mr. Heow Tan
Chief Technology & Quality Officer
Caroline Perez- Dupont
Senior Vice President of Contracts
Dr. Juan Pablo Frias M.D.
Chief Medical Officer
Mr. Ravi Upasani
Executive Vice President of Intellectual Property
Mr. Thomas Andrew Butler
Co-Founder & Chairman
Mr. Ramses M. Erdtmann
Co-Founder, President, Chief Operating Officer & Director